Kiadis draws €20 million from bridge loan with Sanofi

Kiadis Pharma N.V. (“Kiadis” or the “Company”) (Euronext Amsterdam and Brussels: KDS) today announces that the Company has drawn €20 million from the Company’s bridge loan with Sanofi (the “Bridge Loan”) to bridge Kiadis’ capital needs through the closing of the acquisition by Sanofi.

Agreement on its principal terms and the intention to enter into the Bridge Loan were announced on November 2, 2020 and the Bridge Loan has been entered into on January 13, 2021. The Bridge Loan makes available a total of €27.7 million of capital to be borrowed. Further information on the Bridge Loan will be included in the offer memorandum, which is expected to be published in Q1 2021.

Read more…

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH